Fibromyalgia
Conditions
Brief summary
The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously (SC) in reducing pain in adult participants with fibromyalgia (FM). A secondary objective is to evaluate the effect of fremanezumab on other efficacy measures, including pain, quality of life, sleep, fatigue, improvement in health, physical functioning, and mood. Another secondary objective is to evaluate the safety and tolerability of fremanezumab administered SC in adult participants with FM. The total duration of participant participation in the study is planned to be 21 weeks, consisting of a screening period of up to 5 weeks (ranging from 17 to 35 days), and a double-blind treatment period of 16 weeks.
Interventions
DRUGFremanezumab
Fremanezumab will be administered per dose and schedule specified in the arm description.
DRUGPlacebo
Placebo matching to fremanezumab will be administered per schedule specified in the arm description.
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* approved for study participation by the Fibromyalgia Eligibility Review Committee * body mass index of 18.5 to 45 kilograms (kg)/square meter (m\^2) and a body weight ≥45 kg * agree to use only acetaminophen as rescue medication for FM-related pain (up to 1000 mg per dose and not to exceed 3000 mg/day for any indication throughout the study period) * non-pharmacologic interventions (including normal daily exercise routines, chiropractic care, physical therapy, psychotherapy, and massage therapy) are unchanged for a minimum of 30 days prior to screening and will remain unchanged throughout the study * agree to maintain a usual and unchanged physical exercise regimen * must be of nonchildbearing potential or, defined as: * women surgically sterile by documented complete hysterectomy, bilateral oophorectomy, or * bitubal ligations or confirmed to be postmenopausal (at least 1 year since last menstrual period) and * menopausal women confirmed by a follicle-stimulating hormone \>35 units (U)/liter (L) * men surgically sterile by documented vasectomy OR If of childbearing potential, patients must meet any of the following criteria: * must use highly effective contraception method with their partners during the entire study period and for 5 months after the last dose of the study drug. * sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period. * female participants of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-HCG) pregnancy test at screening (confirmed by urine dipstick β-HCG pregnancy test at baseline). * must agree not to participate in another interventional study from the screening period through the end of study (EOS) visit o Additional criteria apply, please contact the investigator for more information
Exclusion criteria
* unable or unwilling to discontinue/washout of prohibited medications * ongoing pain that would confound or interfere with the assessment of the participant's FM pain or require excluded therapies during the participant's participation in this study. * surgery planned during the study period * receiving prophylactic treatment for migraine-related disorders, including topiramate, valproic acid, onabotulinumtoxinA, amitriptyline, and nortriptyline * known history of clinically significant or unstable hematologic, cardiac, or thromboembolic events * known history of suicide attempt, suicidal behavior, or suicidal ideation within the last 12 months * lifetime history of any psychotic and/or bipolar disorder * current, untreated, moderate or severe major depressive disorder and/or anxiety * known history of hypersensitivity reactions to injected proteins, including monoclonal antibodies (mAbs) and animal venoms, or a history of Stevens-Johnson Syndrome/toxic epidermal necrolysis syndrome o Additional criteria apply, please contact the investigator for more information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Weekly Average of the Daily Average Pain Intensity-Numerical Rating Scale (PI-NRS) Score Over the Past 24 Hours at Week 12 | Baseline, Week 12 | The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indicating more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. Baseline was defined as the last 14 days before the first dose of study drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Responder Rate of the Patient Global Impression of Change (PGIC) Rating: Number of Participants Who Were Much Improved or Very Much Improved at Week 12 | Week 12 | The PGIC scale evaluates all aspects of participants' health and assesses if there has been an improvement or decline in clinical status since the start of the study. Participants recorded responses to the PGIC scale at Week 12. Improvement was recorded on a 7-point scale, with 1 = very much improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. Scale much improved or very much improved were considered improved. |
| Number of Participants Who Experienced ≥30% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | Week 12 | The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. |
| Number of Participants Who Experienced ≥50% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | Week 12 | The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. |
| Change From Baseline in the Weekly Average of Daily Worst PI-NRS Score Over Past 24 Hours at Week 12 | Baseline, Week 12 | The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily worst PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. Baseline was defined as the last 14 days before the first dose of study drug. |
| Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form (SF) 8a T-score at Week 12 | Baseline, Week 12 | The PROMIS SF8a scale contains 8 items and assesses sleep disturbance over the past 7 days. One item assessing overall sleep quality use a scale of very poor, poor, fair, good, or very good. Other 7 items use a scale of not at all, a little bit, somewhat, quite a bit, or very much. Each item of the PROMIS sleep disturbance SF8a is on 5-point scales (1 to 5), with 1 for the lowest sleep disturbance and 5 for the highest sleep disturbance. The total score ranging from 8 (lowest sleep disturbance) to 40 (highest sleep disturbance) was calculated as the summation of 8 non-missing scores. T-score was calculated from the total raw score using the scoring table (PROMIS-Sleep Disturbance Scoring Manual) with a mean of 50 and a standard deviation of 10. Possible range for T-score is 30 to 80, with higher scores indicating greater severity of sleep impairment. |
| Change From Baseline in the PROMIS Physical Function SF 12a Scale Score at Week 12 | Baseline, Week 12 | The PROMIS physical function scale measures self-reported capability. This includes the functioning of one's upper extremities (dexterity), lower extremities (walking or mobility), and central regions (neck, back), as well as instrumental activities of daily living, such as running errands over the past 7 days. A single physical function capability score is obtained from a SF. The PROMIS physical function SF12a scale contains 12 items with 5-point scales (1 \[not at all\] to 5 \[very much\]) for each item with a total score ranging from 12 (poor physical function) to 60 (better physical function). A higher score indicates greater level of physical capability. Total raw score was calculated as the summation of 12 non-missing scores for participants who can walk 25 feet or summation of 6 non-missing scores for participants who cannot walk for 25 feet. The calculated total raw score was converted into scale score using the scoring tables (PROMIS-Physical Function Scoring Manual). |
| Change From Baseline in the PROMIS Fatigue SF 8a T-Score at Week 12 | Baseline, Week 12 | The PROMIS Fatigue SF8a contains 8 items with 5-point scales (1 \[never\] to 5 \[always\]) for each item over the past 7 days. The total raw score ranges from 8 (lowest level of fatigue) to 40 (highest level of fatigue) was calculated as the summation of 8 non-missing scores. T-score was calculated from the total raw score using the scoring table (PROMIS-Fatigue Scoring Manual) with a mean of 50 and a standard deviation of 10; scores higher than 50 indicate greater fatigue compared to the reference population. |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Baseline up to Week 16 | An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Any AE occurring on or after the first dose of study drug is considered a treatment-emergent AE (TEAE). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. |
| Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | Baseline up to Week 16 | Potentially clinically significant serum chemistry abnormalities included: Blood urea nitrogen ≥10.71 millimoles (mmol)/liter (L) and Gamma-glutamyl transpeptidase (GGT) ≥3 \* upper limit of normal (ULN). |
| Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Baseline, Week 12 | The FIQR is a commonly used instrument in the evaluation of fibromyalgia participants. It contains 21 questions in 3 domains: function (9 questions), overall impact (2 questions), and symptoms (10 questions). Questions are graded on a 0 to 10 numeric scale with 10 being the worst. All questions are framed in the context of the last 7 days. The sub-total score for each domain is the summation of scores in the domain. The function sub-total score ranges from 0 (better) to 90 (worst), with a lower score indicating better (higher) function; overall impact sub-total score ranges from 0 to 20, with a lower score indicating better (lower) impact; the symptoms sub-total score ranges from 0 to 100, with a lower score indicating a better (lower) level of symptoms. Baseline was defined as the last 14 days before the first dose of study drug. |
| Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | Baseline up to Week 16 | — |
| Number of Participants With at Least 1 Clinically Significant Abnormal Vital Signs Value | Baseline up to Week 16 | Clinically significant vital signs abnormalities included: Systolic blood pressure (BP): ≤90 millimeters of mercury (mmHg) and decrease from baseline of 20 mm Hg; Diastolic BP: ≥105 mmHg and increase from baseline of ≥15 mmHg or ≤50 mmHg and decrease from baseline of ≥15 mmHg. |
| Number of Participants With at Least 1 Physical Examination Abnormal Finding | Baseline up to Week 16 | Physical examination included: General appearance, HEENT (head, ears, eyes, nose, and throat examination), chest and lungs, heart, cardiovascular, abdomen, musculoskeletal, skin, lymph nodes, neurological, and extremities/back. |
| Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Baseline to Week 16 | The number of participants with a difference (shift) from baseline in any of the following ECG parameters is reported by group: heart rate, PR interval, QRS interval, RR interval, QT interval corrected usingthe Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB). Shifts represented as Baseline - endpoint value (last observed post-baseline value). |
| Number of Participants With at Least 1 Injection Site AE | Baseline up to Week 16 | Injection site AEs included injection site pain, injection site erythema, injection site induration, injection site pruritus, injection site bruising, injection site nodule, injection site swelling, and injection site warmth. |
| Number of Participants With Hypersensitivity/Anaphylaxis Reactions | Baseline up to Week 16 | — |
| Time to Withdrawal of Treatment Due to Lack of Efficacy | Baseline up to Week 16 | — |
| Time to Withdrawal of Treatment Due to AEs | Baseline up to Week 16 | — |
| Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | Baseline up to Week 16 | Potentially clinically significant hematological abnormalities included: White blood cells (WBCs) count ≤3.0 \* 10\^9/L; Hemoglobin ≤95 grams (g)/L in females; Hematocrit \<0.32 L/L in females; Platelets ≥700 \* 10\^9/L; and Eosinophils/Leukocytes ≥10%. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo matched to fremanezumab SC on Days 1, 29, 57, and 85. | 64 |
| Fremanezumab Dose A Participants received fremanezumab SC on Days 1, 29, and 57 and placebo matched to fremanezumab SC on Day 85. | 62 |
| Fremanezumab Dose B Participants received fremanezumab SC on Days 1, 29, and 57 and placebo matched to fremanezumab SC on Day 85. | 63 |
| Total | 189 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 | 3 |
| Overall Study | Lack of Efficacy | 2 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 1 | 1 |
| Overall Study | Non-compliance with study drug | 0 | 0 | 1 |
| Overall Study | Other than specified | 9 | 11 | 8 |
| Overall Study | Withdrawal by Subject | 11 | 3 | 5 |
Baseline characteristics
| Characteristic | Placebo | Fremanezumab Dose A | Fremanezumab Dose B | Total |
|---|---|---|---|---|
| Age, Continuous | 51.4 years STANDARD_DEVIATION 11.54 | 52.3 years STANDARD_DEVIATION 11.75 | 52.2 years STANDARD_DEVIATION 12.59 | 51.9 years STANDARD_DEVIATION 11.91 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 6 Participants | 9 Participants | 7 Participants | 22 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 58 Participants | 53 Participants | 55 Participants | 166 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Race American Indian or Alaska Native | 0 Participants | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Asian | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Race Black or African American | 5 Participants | 9 Participants | 5 Participants | 19 Participants |
| Race/Ethnicity, Customized Race Other | 1 Participants | 2 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized Race White | 58 Participants | 50 Participants | 54 Participants | 162 Participants |
| Sex: Female, Male Female | 60 Participants | 59 Participants | 59 Participants | 178 Participants |
| Sex: Female, Male Male | 4 Participants | 3 Participants | 4 Participants | 11 Participants |
| Weekly Average of the Daily Average Pain Intensity-Numerical Rating Scale (PI-NRS) Score | 5.6 units on a scale STANDARD_DEVIATION 1.05 | 5.8 units on a scale STANDARD_DEVIATION 1.03 | 6.0 units on a scale STANDARD_DEVIATION 1.11 | 5.8 units on a scale STANDARD_DEVIATION 1.07 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 64 | 0 / 62 | 0 / 63 |
| other Total, other adverse events | 8 / 64 | 14 / 62 | 10 / 63 |
| serious Total, serious adverse events | 1 / 64 | 1 / 62 | 1 / 63 |
Outcome results
Primary
Change From Baseline in the Weekly Average of the Daily Average Pain Intensity-Numerical Rating Scale (PI-NRS) Score Over the Past 24 Hours at Week 12
The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indicating more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. Baseline was defined as the last 14 days before the first dose of study drug.
Time frame: Baseline, Week 12
Population: Modified intent-to-treat (mITT) analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Weekly Average of the Daily Average Pain Intensity-Numerical Rating Scale (PI-NRS) Score Over the Past 24 Hours at Week 12 | -1.5 units on a scale | Standard Deviation 1.79 |
| Fremanezumab Dose A | Change From Baseline in the Weekly Average of the Daily Average Pain Intensity-Numerical Rating Scale (PI-NRS) Score Over the Past 24 Hours at Week 12 | -1.2 units on a scale | Standard Deviation 1.58 |
| Fremanezumab Dose B | Change From Baseline in the Weekly Average of the Daily Average Pain Intensity-Numerical Rating Scale (PI-NRS) Score Over the Past 24 Hours at Week 12 | -1.3 units on a scale | Standard Deviation 1.61 |
Comparison: Analysis was performed using a Mixed Model Repeated Measures (MMRM) model with change from baseline in the weekly average of the daily average PI-NRS score over the past 24 hours at weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 as the dependent variable, sex, age group at FM onset, week, treatment, and treatment-by-week interaction as fixed factors, and baseline average of the daily average PI-NRS score as a covariate.p-value: 0.796395% CI: [-0.46, 0.6]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM model with change from baseline in the weekly average of the daily average PI-NRS score over the past 24 hours at weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 as the dependent variable, sex, age group at FM onset, week, treatment, and treatment-by-week interaction as fixed factors, and baseline average of the daily average PI-NRS score as a covariate.p-value: 0.862995% CI: [-0.48, 0.58]Mixed Models Analysis
Secondary
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form (SF) 8a T-score at Week 12
The PROMIS SF8a scale contains 8 items and assesses sleep disturbance over the past 7 days. One item assessing overall sleep quality use a scale of very poor, poor, fair, good, or very good. Other 7 items use a scale of not at all, a little bit, somewhat, quite a bit, or very much. Each item of the PROMIS sleep disturbance SF8a is on 5-point scales (1 to 5), with 1 for the lowest sleep disturbance and 5 for the highest sleep disturbance. The total score ranging from 8 (lowest sleep disturbance) to 40 (highest sleep disturbance) was calculated as the summation of 8 non-missing scores. T-score was calculated from the total raw score using the scoring table (PROMIS-Sleep Disturbance Scoring Manual) with a mean of 50 and a standard deviation of 10. Possible range for T-score is 30 to 80, with higher scores indicating greater severity of sleep impairment.
Time frame: Baseline, Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form (SF) 8a T-score at Week 12 | -4.7 T-score | Standard Deviation 8.39 |
| Fremanezumab Dose A | Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form (SF) 8a T-score at Week 12 | -2.6 T-score | Standard Deviation 8.31 |
| Fremanezumab Dose B | Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Short Form (SF) 8a T-score at Week 12 | -3.1 T-score | Standard Deviation 6.86 |
Secondary
Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12
The FIQR is a commonly used instrument in the evaluation of fibromyalgia participants. It contains 21 questions in 3 domains: function (9 questions), overall impact (2 questions), and symptoms (10 questions). Questions are graded on a 0 to 10 numeric scale with 10 being the worst. All questions are framed in the context of the last 7 days. The sub-total score for each domain is the summation of scores in the domain. The function sub-total score ranges from 0 (better) to 90 (worst), with a lower score indicating better (higher) function; overall impact sub-total score ranges from 0 to 20, with a lower score indicating better (lower) impact; the symptoms sub-total score ranges from 0 to 100, with a lower score indicating a better (lower) level of symptoms. Baseline was defined as the last 14 days before the first dose of study drug.
Time frame: Baseline, Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Impact Subscore | -2.0 units on a scale | Standard Deviation 4.6 |
| Placebo | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Symptoms Subscore | -9.1 units on a scale | Standard Deviation 13.99 |
| Placebo | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Functional Subscore | -9.5 units on a scale | Standard Deviation 16.26 |
| Fremanezumab Dose A | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Impact Subscore | -1.6 units on a scale | Standard Deviation 5 |
| Fremanezumab Dose A | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Symptoms Subscore | -4.0 units on a scale | Standard Deviation 13.76 |
| Fremanezumab Dose A | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Functional Subscore | -4.7 units on a scale | Standard Deviation 18.54 |
| Fremanezumab Dose B | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Symptoms Subscore | -8.1 units on a scale | Standard Deviation 15.19 |
| Fremanezumab Dose B | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Functional Subscore | -6.7 units on a scale | Standard Deviation 13.35 |
| Fremanezumab Dose B | Change From Baseline in the Individual Components of the Fibromyalgia Impact Questionnaire Revised (FIQR) Score: Symptom Subscore, Impact Subscore, and Functional Subscore at Week 12 | Change at Week 12 in Impact Subscore | -2.2 units on a scale | Standard Deviation 4.27 |
Secondary
Change From Baseline in the PROMIS Fatigue SF 8a T-Score at Week 12
The PROMIS Fatigue SF8a contains 8 items with 5-point scales (1 \[never\] to 5 \[always\]) for each item over the past 7 days. The total raw score ranges from 8 (lowest level of fatigue) to 40 (highest level of fatigue) was calculated as the summation of 8 non-missing scores. T-score was calculated from the total raw score using the scoring table (PROMIS-Fatigue Scoring Manual) with a mean of 50 and a standard deviation of 10; scores higher than 50 indicate greater fatigue compared to the reference population.
Time frame: Baseline, Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the PROMIS Fatigue SF 8a T-Score at Week 12 | -3.9 T-score | Standard Deviation 8.61 |
| Fremanezumab Dose A | Change From Baseline in the PROMIS Fatigue SF 8a T-Score at Week 12 | -3.3 T-score | Standard Deviation 6.92 |
| Fremanezumab Dose B | Change From Baseline in the PROMIS Fatigue SF 8a T-Score at Week 12 | -3.3 T-score | Standard Deviation 7.97 |
Secondary
Change From Baseline in the PROMIS Physical Function SF 12a Scale Score at Week 12
The PROMIS physical function scale measures self-reported capability. This includes the functioning of one's upper extremities (dexterity), lower extremities (walking or mobility), and central regions (neck, back), as well as instrumental activities of daily living, such as running errands over the past 7 days. A single physical function capability score is obtained from a SF. The PROMIS physical function SF12a scale contains 12 items with 5-point scales (1 \[not at all\] to 5 \[very much\]) for each item with a total score ranging from 12 (poor physical function) to 60 (better physical function). A higher score indicates greater level of physical capability. Total raw score was calculated as the summation of 12 non-missing scores for participants who can walk 25 feet or summation of 6 non-missing scores for participants who cannot walk for 25 feet. The calculated total raw score was converted into scale score using the scoring tables (PROMIS-Physical Function Scoring Manual).
Time frame: Baseline, Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the PROMIS Physical Function SF 12a Scale Score at Week 12 | 1.8 units on a scale | Standard Deviation 3.67 |
| Fremanezumab Dose A | Change From Baseline in the PROMIS Physical Function SF 12a Scale Score at Week 12 | 0.7 units on a scale | Standard Deviation 4.28 |
| Fremanezumab Dose B | Change From Baseline in the PROMIS Physical Function SF 12a Scale Score at Week 12 | 1.0 units on a scale | Standard Deviation 3.59 |
Secondary
Change From Baseline in the Weekly Average of Daily Worst PI-NRS Score Over Past 24 Hours at Week 12
The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily worst PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week. Baseline was defined as the last 14 days before the first dose of study drug.
Time frame: Baseline, Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Weekly Average of Daily Worst PI-NRS Score Over Past 24 Hours at Week 12 | -1.6 units on a scale | Standard Deviation 2 |
| Fremanezumab Dose A | Change From Baseline in the Weekly Average of Daily Worst PI-NRS Score Over Past 24 Hours at Week 12 | -1.4 units on a scale | Standard Deviation 1.54 |
| Fremanezumab Dose B | Change From Baseline in the Weekly Average of Daily Worst PI-NRS Score Over Past 24 Hours at Week 12 | -1.3 units on a scale | Standard Deviation 1.8 |
Secondary
Number of Participants Who Experienced ≥30% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12
The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week.
Time frame: Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Who Experienced ≥30% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | 19 Participants |
| Fremanezumab Dose A | Number of Participants Who Experienced ≥30% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | 18 Participants |
| Fremanezumab Dose B | Number of Participants Who Experienced ≥30% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | 18 Participants |
Secondary
Number of Participants Who Experienced ≥50% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12
The PI-NRS is an 11-point pain intensity numerical rating scale where 0=no pain and 10=worst possible pain; higher scores indication more pain. Weekly average of the daily average PI-NRS pain score over the past 24 hours was derived using formula: Summation of non-missing efficacy variable in an analysis week divided by the number of days with non-missing efficacy variable in the analysis week.
Time frame: Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Who Experienced ≥50% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | 11 Participants |
| Fremanezumab Dose A | Number of Participants Who Experienced ≥50% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | 6 Participants |
| Fremanezumab Dose B | Number of Participants Who Experienced ≥50% Reduction From Baseline in Weekly Average of Daily Average PI-NRS Score at Week 12 | 8 Participants |
Secondary
Number of Participants With at Least 1 Clinically Significant Abnormal Vital Signs Value
Clinically significant vital signs abnormalities included: Systolic blood pressure (BP): ≤90 millimeters of mercury (mmHg) and decrease from baseline of 20 mm Hg; Diastolic BP: ≥105 mmHg and increase from baseline of ≥15 mmHg or ≤50 mmHg and decrease from baseline of ≥15 mmHg.
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Clinically Significant Abnormal Vital Signs Value | 1 Participants |
| Fremanezumab Dose A | Number of Participants With at Least 1 Clinically Significant Abnormal Vital Signs Value | 2 Participants |
| Fremanezumab Dose B | Number of Participants With at Least 1 Clinically Significant Abnormal Vital Signs Value | 0 Participants |
Secondary
Number of Participants With at Least 1 Injection Site AE
Injection site AEs included injection site pain, injection site erythema, injection site induration, injection site pruritus, injection site bruising, injection site nodule, injection site swelling, and injection site warmth.
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Injection Site AE | 5 Participants |
| Fremanezumab Dose A | Number of Participants With at Least 1 Injection Site AE | 8 Participants |
| Fremanezumab Dose B | Number of Participants With at Least 1 Injection Site AE | 7 Participants |
Secondary
Number of Participants With at Least 1 Physical Examination Abnormal Finding
Physical examination included: General appearance, HEENT (head, ears, eyes, nose, and throat examination), chest and lungs, heart, cardiovascular, abdomen, musculoskeletal, skin, lymph nodes, neurological, and extremities/back.
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Physical Examination Abnormal Finding | 24 Participants |
| Fremanezumab Dose A | Number of Participants With at Least 1 Physical Examination Abnormal Finding | 25 Participants |
| Fremanezumab Dose B | Number of Participants With at Least 1 Physical Examination Abnormal Finding | 28 Participants |
Secondary
Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value
Potentially clinically significant hematological abnormalities included: White blood cells (WBCs) count ≤3.0 \* 10\^9/L; Hemoglobin ≤95 grams (g)/L in females; Hematocrit \<0.32 L/L in females; Platelets ≥700 \* 10\^9/L; and Eosinophils/Leukocytes ≥10%.
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | 4 Participants |
| Fremanezumab Dose A | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | 3 Participants |
| Fremanezumab Dose B | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | 7 Participants |
Secondary
Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value
Potentially clinically significant serum chemistry abnormalities included: Blood urea nitrogen ≥10.71 millimoles (mmol)/liter (L) and Gamma-glutamyl transpeptidase (GGT) ≥3 \* upper limit of normal (ULN).
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | 2 Participants |
| Fremanezumab Dose A | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | 2 Participants |
| Fremanezumab Dose B | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | 1 Participants |
Secondary
Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | 0 Participants |
| Fremanezumab Dose A | Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | 0 Participants |
| Fremanezumab Dose B | Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | 0 Participants |
Secondary
Number of Participants With Hypersensitivity/Anaphylaxis Reactions
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Hypersensitivity/Anaphylaxis Reactions | 0 Participants |
| Fremanezumab Dose A | Number of Participants With Hypersensitivity/Anaphylaxis Reactions | 1 Participants |
| Fremanezumab Dose B | Number of Participants With Hypersensitivity/Anaphylaxis Reactions | 0 Participants |
Secondary
Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters
The number of participants with a difference (shift) from baseline in any of the following ECG parameters is reported by group: heart rate, PR interval, QRS interval, RR interval, QT interval corrected usingthe Fridericia formula (QTcF) and QT interval corrected using the Bazett's formula (QTcB). Shifts represented as Baseline - endpoint value (last observed post-baseline value).
Time frame: Baseline to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = participants with both baseline and postbaseline ECG value.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Normal | 39 Participants |
| Placebo | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Abnormal, not clinically significant | 9 Participants |
| Placebo | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Abnormal, clinically significant | 0 Participants |
| Placebo | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Normal | 4 Participants |
| Placebo | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Abnormal, not clinically significant | 6 Participants |
| Placebo | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Abnormal, clinically significant | 0 Participants |
| Fremanezumab Dose A | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Abnormal, clinically significant | 0 Participants |
| Fremanezumab Dose A | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Normal | 36 Participants |
| Fremanezumab Dose A | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Normal | 2 Participants |
| Fremanezumab Dose A | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Abnormal, not clinically significant | 6 Participants |
| Fremanezumab Dose A | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Abnormal, not clinically significant | 11 Participants |
| Fremanezumab Dose A | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Abnormal, clinically significant | 0 Participants |
| Fremanezumab Dose B | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Abnormal, not clinically significant | 6 Participants |
| Fremanezumab Dose B | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Abnormal, clinically significant | 1 Participants |
| Fremanezumab Dose B | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Abnormal, clinically significant | 1 Participants |
| Fremanezumab Dose B | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Normal | 5 Participants |
| Fremanezumab Dose B | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Normal - Normal | 34 Participants |
| Fremanezumab Dose B | Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters | Abnormal - Abnormal, not clinically significant | 12 Participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Any AE occurring on or after the first dose of study drug is considered a treatment-emergent AE (TEAE). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Week 16
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 34 Participants |
| Fremanezumab Dose A | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 30 Participants |
| Fremanezumab Dose B | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 29 Participants |
Secondary
Responder Rate of the Patient Global Impression of Change (PGIC) Rating: Number of Participants Who Were Much Improved or Very Much Improved at Week 12
The PGIC scale evaluates all aspects of participants' health and assesses if there has been an improvement or decline in clinical status since the start of the study. Participants recorded responses to the PGIC scale at Week 12. Improvement was recorded on a 7-point scale, with 1 = very much improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. Scale much improved or very much improved were considered improved.
Time frame: Week 12
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Responder Rate of the Patient Global Impression of Change (PGIC) Rating: Number of Participants Who Were Much Improved or Very Much Improved at Week 12 | 14 Participants |
| Fremanezumab Dose A | Responder Rate of the Patient Global Impression of Change (PGIC) Rating: Number of Participants Who Were Much Improved or Very Much Improved at Week 12 | 12 Participants |
| Fremanezumab Dose B | Responder Rate of the Patient Global Impression of Change (PGIC) Rating: Number of Participants Who Were Much Improved or Very Much Improved at Week 12 | 11 Participants |
Secondary
Time to Withdrawal of Treatment Due to AEs
Time frame: Baseline up to Week 16
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. There were no participants with evaluable data in the Placebo arm.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fremanezumab Dose A | Time to Withdrawal of Treatment Due to AEs | NA weeks |
| Fremanezumab Dose B | Time to Withdrawal of Treatment Due to AEs | NA weeks |
Secondary
Time to Withdrawal of Treatment Due to Lack of Efficacy
Time frame: Baseline up to Week 16
Population: mITT analysis set included all randomized participants who received at least 1 dose of study drug and at least 1 postbaseline entry of daily average pain intensity using the PI-NRS. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. There were no participants with evaluable data in the Fremanezumab Dose B arm.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to Withdrawal of Treatment Due to Lack of Efficacy | NA weeks |
| Fremanezumab Dose A | Time to Withdrawal of Treatment Due to Lack of Efficacy | NA weeks |